Blurbs

Mizuho Securities Keeps a Buy Rating on uniQure (QURE)

Mizuho Securities analyst Uy Ear maintained a Buy rating on uniQure (QUREResearch Report) today and set a price target of $52.00. The company’s shares closed last Thursday at $18.56.

According to TipRanks.com, Ear is ranked #6087 out of 7895 analysts.

Currently, the analyst consensus on uniQure is a Strong Buy with an average price target of $55.29.

See the top stocks recommended by analysts >>

uniQure’s market cap is currently $717.9M and has a P/E ratio of 2.18.

Based on the recent corporate insider activity of 50 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of QURE in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

uniQure NV engages in the research, development, and commercialization of gene therapies. Its discoveries intend to treat hemophilia, Huntington’s disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, the Netherlands.

Read More on QURE:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More
Videos